Chapter 31
Paraneoplastic Neurological Syndromes
C. A. Vedeler,
J. C. Antoine, B. Giometto, F. Graus,
W. Grisold,
J. Honnorat, P. A. E. Sillevis Smitt,
J. J. G. M. Verschuuren,
R. Voltz,
C. A. Vedeler
Haukeland University Hospital and University of Bergen, Norway
Search for more papers by this authorF. Graus
Institut d'Investigacio Biomedica August Pi I Sunyer (IDIBAPS), Hospital Clinic, University of Barcelona, Spain
Search for more papers by this authorW. Grisold
Kaiser Franz Josef hospital and Ludwig Boltzmann Institute for Neurooncology, Vienna, Austria
Search for more papers by this authorP. A. E. Sillevis Smitt
Erasmus University Medical Center, Rotterdam, The Netherlands
Search for more papers by this authorJ. J. G. M. Verschuuren
Leiden University Medical Center, The Netherlands
Search for more papers by this authorC. A. Vedeler,
J. C. Antoine, B. Giometto, F. Graus,
W. Grisold,
J. Honnorat, P. A. E. Sillevis Smitt,
J. J. G. M. Verschuuren,
R. Voltz,
C. A. Vedeler
Haukeland University Hospital and University of Bergen, Norway
Search for more papers by this authorF. Graus
Institut d'Investigacio Biomedica August Pi I Sunyer (IDIBAPS), Hospital Clinic, University of Barcelona, Spain
Search for more papers by this authorW. Grisold
Kaiser Franz Josef hospital and Ludwig Boltzmann Institute for Neurooncology, Vienna, Austria
Search for more papers by this authorP. A. E. Sillevis Smitt
Erasmus University Medical Center, Rotterdam, The Netherlands
Search for more papers by this authorJ. J. G. M. Verschuuren
Leiden University Medical Center, The Netherlands
Search for more papers by this authorNils Erik Gilhus MD, PhD,
Michael P. Barnes MD, FRCP,
Michael Brainin MD,
Nils Erik Gilhus MD, PhD
Professor
Department of Clinical Medicine, University of Bergen and Department of Neurology, Haukeland University Hospital, Bergen, Norway
Search for more papers by this authorMichael P. Barnes MD, FRCP
Professor of Neurological Rehabilitation Medical Director
University of Newcastle, Hunters Moor Neurorehabilitation Ltd, Newcastle upon Tyne, UK
Search for more papers by this authorMichael Brainin MD
Professor
Department of Clinical Medicine and Prevention, and Center for Clinical Neurosciences, Donau-Universität Krems, Department of Neurology, Landesklinikum Donauregion Tulln Tulln, Austria
Search for more papers by this authorBook Author(s):Nils Erik Gilhus MD, PhD,
Michael P. Barnes MD, FRCP,
Michael Brainin MD,
Nils Erik Gilhus MD, PhD
Professor
Department of Clinical Medicine, University of Bergen and Department of Neurology, Haukeland University Hospital, Bergen, Norway
Search for more papers by this authorMichael P. Barnes MD, FRCP
Professor of Neurological Rehabilitation Medical Director
University of Newcastle, Hunters Moor Neurorehabilitation Ltd, Newcastle upon Tyne, UK
Search for more papers by this authorMichael Brainin MD
Professor
Department of Clinical Medicine and Prevention, and Center for Clinical Neurosciences, Donau-Universität Krems, Department of Neurology, Landesklinikum Donauregion Tulln Tulln, Austria
Search for more papers by this authorSummary
This chapter contains sections titled:
-
Background
-
Methods
-
Paraneoplastic limbic encephalitis
-
Subacute sensory neuronopathy
-
Paraneoplastic opsoclonus-myoclonus
-
Paraneoplastic cerebellar degeneration
-
Lambert-Eaton myasthenic syndrome
-
Paraneoplastic peripheral nerve hyperexcitability syndromes
-
Acknowledgements
-
References
References
- Graus F, Delattre JY, Antoine JC, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 2004; 75: 1135–40.
- Skeie GO, Apostolski S, Evoli A, et al. Guidelines for the treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 2006; 13: 691–9.
- Willison HJ, Ang W, Gilhus NE, et al. EFNS Task force report: a questionairre-based survey on the service provision and quality assurance for determiniation of diagnostic autoantibody tests in European neuroimmunology centres. European Federation of Neurological Societies. Eur J Neurol 2000; 7: 625–8.
- Brainin M, Barnes M, Baron J-C, et al. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces–revised recommendations 2004. Eur J Neurol 2004; 11: 577–81.
- Gultekin SH, Rosenfeld MR, Voltz R, et al. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumor association in 50 patients. Brain 2000; 123: 1481–94.
- Dirr LY, Elster AD, Donofrio PD, Smith M. Evolution of brain abnormalities in limbic encephalitis. Neurology 1990; 40: 1304–6.
-
Provenzale JM, Barboriak DP, Coleman RE. Limbic encephalitis: comparison of FDG PET and MRI findings. Am J Roentgenol 1998; 18: 1659–60.
10.2214/ajr.170.6.9609193 Google Scholar
- Dalmau J, Graus F, Villarejo A, et al. Clinical analysis of anti-Ma2-associated encephalitis. Brain 2004; 127: 1831–44.
- Yu Z, Kryzer TJ, Grisemann GE, et al. CRMP -5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol 2001; 49: 146–54.
- Buckley C, Oger J, Clover L, et al. Potassium channel antibodies in two patients with reversible limbic encephalitis. Ann Neurol 2001; 50: 74–9.
- Pozo -Rosich P, Clover L, Saiz A, et al. Voltage-gated potassium channel antibodies in limbic encephalitis. Ann Neurol 2003; 54: 530–3.
- Vincent A, Buckley C, Schott JM, et al. Potassium Channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of encephalitis. Brain 2004; 127: 701–12.
- Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis:case series and analysis of the effects of antibodies. Lancet Neurol 2008; 7: 1091–8.
- Lai M, Hughes EG, Peng X, et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol 2009; 65: 424–34.
- Graus F, Saiz A, Lai M, et al. Neuronal surface antigen antibodies in limbic encephalitis: clinical-immunologic associations. Neurology 2008; 71: 930–6.
- Graus F, Keime-Guibert F, Reòe R, et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 2001; 124: 1138–48.
- Linke R, Schroeder M, Helmberger T, Voltz R. Antibody-positive paraneoplastic neurologic syndromes: value of CT and PET for tumor diagnosis. Neurology 2004; 63: 282–6.
- Younes-Mhenni S, Janier MF, Cinotti L, et al. FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes. Brain 2004; 127: 2331–8.
- Horwich MS, Cho L, Porro RS, Posner JB. Subacute sensory neuropathy: a remote effect of carcinoma. Ann Neurol 1977; 2: 7–19.
- Graus F, Bonaventura I, Uchya M, et al. Indolent anti-Hu-associated paraneoplastic sensory neuropathy. Neurology 1994; 44: 2258–61.
- Camdessanché JP, Jousserand G, Ferraud K, et al. The pattern and diagnostic criteria of sensory neuronopathy. The pattern and diagnostic criteria of sensory neuronopathy. A case control study. Brain 2009; 132: 1723–33.
- Camdesssance JP, Antoine JC, Honnorat J, et al. Paraneoplastic peripheral neuropathy associated with anti-Hu antibodies. A clinical and electrophysiological study of 20 patients. Brain 2002; 125: 166–75.
- Younger DS, Dalmau J, Inghirami G, et al. Anti-Hu-associated peripheral nerve and muscle microvasculitis. Neurology 1994; 44: 181–3.
- Molinuevo JL, Graus F, Serrano C, et al. Utility of anti-Hu antibodies in the diagnosis of paraneoplastic sensory neuropathy. Ann Neurol 1998; 4: 976–80.
- Antoine JC, Honnorat J, Camdesssance JP, et al. Paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy. Ann Neurol 2001; 49: 214–21.
- Honnorat J, Cartalat-Carel S, Ricard D, et al. Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies. J Neurol Neurosurg Psychiatry 2009; 80: 412–6.
- Honnorat J, Antoine JC, Derrington E, et al. Antibodies to a subpopulation of glial cells and a 66 kDa developmental protein in patients with paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 1996; 61: 270–8.
- Uchuya M, Graus F, Vega F, et al. Intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with antineuronal autoantibodies. J Neurol Neurosurg Psychiatry 1996; 60: 388–39.
- Keime-Guibert F, Graus F, Fleury A, et al. Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry 2000; 68: 479–82.
- Vernino S, O'Neill BP, Marks RS, et al. Immunomodulatory treatment trial for paraneoplastic neurological disorders. Neuro-Oncol 2004; 6: 55–62.
- Shams’ili S, de Beukelaar J, Gratama JW, et al. An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes. J Neurol 2006; 253: 16–20.
- Peterson K, Rosenblum MK, Kotanides H, Posner JB. Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology 1992; 42: 1931–7.
- Mason WP, Graus F, Lang B, et al. Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome. Brain 1997; 120: 1279–300.
- Bernal F, Shams'ili S, Rojas I, et al. Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin's disease. Neurology 2003; 60: 230–4.
- Shams'ili S, Grefkens J, de Leeuw B, et al. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50. Patients Brain 2003; 126: 1409–18.
- Fukuda T, Motomura M, Nakao Y, et al. Reduction of P/Q-type calcium channels in the postmortem cerebellum of paraneoplastic cerebellar degeneration with Lambert-Eaton myasthenic syndrome. Ann Neurol 2003; 53: 21–8.
- Widdess-Walsh P, Tavee JO, Schuele S, Stevens GH. Response to intravenous immunoglobulin in anti-Yo associated paraneoplastic cerebellar degeneration: case report and review of the literature. J Neurooncol 2003; 63: 187–90.
- Rojas I, Graus F, Keime-Guibert F, et al. Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology 2000; 55: 713–5.
- Anderson NE, Budde-Steffen C, Rosenblum MK, et al. Opsoclonus, myoclonus, ataxia, and encephalopathy in adults with cancer: a distinct paraneoplastic syndrome. Medicine 1988; 67: 100–9.
- Buttner U, Straube A, Handke V. Opsoclonus and ocular flutter. Nervenarzt 1997; 68: 633–7.
- Straube A, Leigh RJ, Bronstein A, et al. EFNS task force-therapy of nystagmus and oscillopsia. Eur J Neurol 2004; 11: 83–9.
- Dropcho EJ, Kline LB, Riser J. Antineuronal (anti-Ri) antibodies in a patient with steroid-responsive opsoclonus-myoclonus. Neurology 1993; 43: 207–11.
- Mitchell WG, Davalos-Gonzalez Y, Brumm VL, et al. Opsoclonus-ataxia caused by childhood neuroblastoma: developmental and neurologic sequelae. Pediatrics 2002; 109: 86–98.
- Gambini C, Conte M, Bernini G, et al. Neuroblastic tumors associated with opsoclonus-myoclonus syndrome: histological, immunohistochemical and molecular features of 15 Italian cases. Virchows Arch 2003; 442: 555–62.
- Bataller L, Graus F, Saiz A, Vilchez JJ. Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus. Brain 2001; 124: 437–43.
- Voltz R. Paraneoplastic neurological syndromes: an update on diagnosis, pathogenesis, and therapy. Lancet Neurol 2002; 1: 294–305.
- Darnell JC, Posner JB. Paraneoplastic syndromes involving the nervous system. N Engl J Med 2003; 349: 1543–54.
- Berger JR, Mehari E. Paraneoplastic opsoclonus-myoclonus secondary to malignant melanoma. J Neurooncol 1999; 41: 43–5.
- Jung KY, Youn J, Chung CS. Opsoclonus-myoclonus syndrome in an adult with malignant melanoma. J Neurol 2006; 253: 942–3.
- Zamecnik J, Cerny R, Bartos A, et al. Paraneoplastic opsoclonus-myoclonus syndrome associated with malignant fibrous histiocytoma: neuropathological findings. Cesk Patol 2004; 40: 63–7.
- Fitzpatrick AS, Gray OM, McConville J, McDonnell GV. Opsoclonus-myoclonus syndrome associated with benign ovarian teratoma. Neurology 2008; 70: 1292–3.
- Van Diest D, De Raeve H, Claes J, et al. Paraneoplastic opsoclonus-myoclonus-ataxia (OMA) syndrome in an adult patient with esthesioneuroblastoma. J Neurol 2008; 255: 594–6.
- Vigliani MC, Palmucci L, Polo P, et al. Paraneoplastic opsoclonus-myoclonus associated with renal cell carcinoma and responsive to tumour ablation. J Neurol Neurosurg Psychiatry 2001; 70: 814–5.
- Kumar A, Lajara-Nanson WA, Neilson RW Jr. Paraneoplastic opsoclonus-myoclonus syndrome: initial presentation of non-Hodgkins lymphoma. J Neurooncol 2005; 73: 43–5.
- Ducrocq X, Petit J, Taillandier L, et al. Paraneoplastic opsoclonus-myoclonus syndrome revealing T -cell lymphoma. Presse Med 1999; 28: 330–3.
- Antunes NL, Khakoo Y, Matthay KK, et al. Antineuronal antibodies in patients with neuroblastoma and paraneoplastic opsoclonus-myoclonus. J Pediatr Hematol Oncol 2000; 22: 315–20.
- Pranzatelli MR, Tate ED, Wheeler A, et al. Screening for autoantibodies in children with opsoclonus-myoclonus-ataxia. Pediatr Neurol 2002; 27: 384–7.
- Bataller L, Rosenfeld MR, Graus F, Vilchez JJ, et al. Autoantigen diversity in the opsoclonus-myoclonus syndrome. Ann Neurol 2003; 53: 347–53.
-
Prestigiacomo CJ, Balmaceda C, Dalmau J. Anti-Ri-associated paraneoplastic opsoclonus-ataxia syndrome in a man with transitional cell carcinoma. Cancer 2001; 91: 1423–8.
10.1002/1097-0142(20010415)91:8<1423::AID-CNCR1148>3.0.CO;2-F CAS PubMed Web of Science® Google Scholar
- Wong AM, Musallam S, Tomlinson RD, et al. Opsoclonus in three dimensions: oculographic, neuropathologic and modelling correlates. J Neurol Sci 2001; 189: 71–81.
- Wirtz PW, Sotodeh M, Nijnuis M, et al. Difference in distribution of muscle weakness between myasthenia gravis and the Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 2002; 73: 766–8.
- Swart JF, de Kraker J, van der Lely N. Metaiodobenzylguanidine total-body scintigraphy required for revealing occult neuroblastoma in opsoclonus -myoclonus syndrome. Eur J Pediatr 2002; 161: 255–8.
- Hayward K, Jeremy RJ, Jenkins S, et al. Long-term neurobehavioral outcomes in children with neuroblastoma and opsoclonus-myoclonus-ataxia syndrome: relationship to MRI findings and anti-neuronal antibodies. J Pediatr 2001; 139: 552–9.
- Rudnick E, Khakoo Y, Antunes NL, et al. Opsoclonus- myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies–a report from the Children's Cancer Group Study. Med Pediatr Oncol 2001; 36: 612–22.
- Ertle F, Behnisch W, Al Mulla NA, et al. Treatment of neuroblastoma-related opsoclonus-myoclonus-ataxia syndrome with high-dose dexamethasone pulses. Pediatr Blood Cancer 2008; 50: 683–7.
- Catsman-Berrevoets CE, Aarsen FK, van Hemsbergen ML. Improvement of neurological status and quality of life in children with opsoclonus myoclonus syndrome at long-term follow -up. Pediatr Blood Cancer 2009; 53: 1048–53.
- Nitschke M, Hochberg F, Dropcho E. Improvement of paraneoplastic opsoclonus-myoclonus after protein A column therapy. N Engl J Med 1995; 332: 192.
- Jongen JL, Moll WJ, Sillevis Smitt PA, et al. Anti-Ri positive opsoclonus-myoclonus-ataxia in ovarian duct cancer. J Neurol 1988; 245: 691–2.
- Pranzatelli MR, Tate ED, Dukart WS, et al. Sleep disturbance and rage attacks in opsoclonus-myoclonus syndrome: response to trazodone. J Pediatr 2005; 147: 372–8.
- O'Neill JH, Murray NM, Newsom-Davis J. The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain 1988; 111: 577–96.
- Titulaer MJ, Wirtz PW, Willems LNA, et al. Screening for small cell lung cancer: a follow-up study of patients with Lambert-Eaton myasthenic syndrome. J Clin Oncol 2008; 26: 4276–81.
- Motomura M, Johnston I, Lang B, et al. An improved diagnostic assay for Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 1995; 58: 85–7.
- Wirtz PW, Willcox N, van der Slik AR, et al. HLA and smoking in prediction and prognosis of small cell lung cancer in autoimmune Lambert-Eaton myasthenic syndrome. J Neuroimmunol 2005; 159: 230–7.
- Sabater L, Titulaer M, Saiz A, et al. SOX1 antibodies are markers of paraneoplastic Lambert Eatonmyasthenic syndrome. Neurology 2008; 70: 924–8.
- Titulaer MJ, Klooster R, Potman M, et al. SOX antibodies in small-cell lung cancer and Lambert-Eaton myasthenic syndrome: frequency and relation with survival. J Clin Oncol 2009; 27: 4260–7.
- Chalk CH, Murray NM, Newsom-Davis J, O'Neill JH, Spiro SG. Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma. Neurology 1990; 40: 1552–6.
- Maddison P, Newsom-Davis J, Mills KR, Souhami RL. Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma. Lancet 1999; 353: 117–8.
- McEvoy KM, Windebank AJ, Daube JR, Low PA. 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. N Engl J Med 1989; 321: 1567–71.
- Wirtz PW, Verschuuren JJ, van Dijk JG, et al. Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert–Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study. Clin Pharmacol Ther 2009; 86: 44–8.
- Hart IK, Waters C, Vincent A, et al. Autoantibodies detected to expressed potassium channels are implicated in neuromyotonia. Ann Neurol 1997; 41: 238–46.
- Hart IK, Maddison P, Newsom-Davis J, et al. Phenotypic variants of peripheral nerve hyperexcitability. Brain 2002; 125: 1887–95.
- Caress JB, Abend WK, Preston DC, Logigian EL. A case of Hodgkin's lymphoma producing neuromyotonia. Neurology 1997; 49: 258–9.
- Lahrmann H, Albrecht G, Drlicek M, et al. Acquired neuromyotonia and peripheral neuropathy in a patient with Hodgkin's disease. Muscle Nerve 2001; 24: 834–8.
- Zifko U, Drlicek M, Machacek E, et al. Syndrome of continuous muscle fiber activity and plasmacytoma with IgM paraproteinemia. Neurology 1994; 44: 560–1.
- Newsom-Davis J, Mills KR. Immunological associations of acquired neuromyotonia (Isaacs'syndrome). Report of five cases and literature review. Brain 1993; 116: 453–69.
- Toepfer M, Schroeder M, Unger JM, et al. Neuromyotonia, myoclonus, sensory neuropathy and cerebellar symptoms in a patient with antibodies to neuronal nucleoproteins (anti-Hu-antibodies). Clin Neurol Neurosurg 1999; 101: 207–9.
- Hayat GR, Kulkantrakorn K, Campbell WW, Giuliani MJ. Neuromyotonia: autoimmune pathogenesis and response to immune modulating therapy. J Neurol Sci 2000; 181: 38–43.
- Shillito P, Molenaar PC, Vincent A, et al. Acquired neuromyotonia: evidence for autoantibodies directed against K+ channels of peripheral nerves. Ann Neurol 1995; 38: 714–22.
- Alessi G, De Reuck J, De Bleecker J, Vancayzeele S. Successful immunoglobulin treatment in a patient with neuromyotonia. Clin Neurol Neurosurgery 2000; 102: 173–5.
- Ishii A, Hayashi A, Ohkoshi N, et al. Clinical evaluation of plasma exchange and high dose intravenous immunoglobulin in a patient with Isaacs' syndrome. J Neurol Neurosurg Psychiatry 1994; 57: 840–2.
- van den Berg JS, van Engelen BG, Boerman RH, de Baets MH. Acquired neuromyotonia: superiority of plasma exchange over high-dose intravenous human immunoglobulin. J Neurol 1999; 246: 623–5.
- Nakatsuji Y, Kaido M, Sugai F, et al. Isaacs' syndrome successfully treated by immunoadsorption plasmapheresis. Acta Neurol Scand 2000; 102: 271–3.
